Ocular Therapeutix Inc (OCUL)

Drugs • Health Care

Stock AI

News & Reports

August 03, 2026 Ocular Therapeutix Inc. Reports Second Quarter 2026 Financial Results and Business Highlights Ocular Therapeutix reports steady financials for Q2 2026 with a focus on advancing its AXPAXLI NDA submission for wet AMD. Key insights from clinical trials indicate significant potential in reducing patient treatment burdens, enhancing adherence, and improving outcomes. The company remains well-positioned for growth with a strong cash reserve.

August 03, 2026 Ocular Therapeutix Inc. Reports Mixed Financial Results for Q2 2026 Ocular Therapeutix Inc. reported a net product revenue of $13.5 million for Q2 2026 but faced a net loss of $78.76 million due to increased R&D costs. The company is advancing its investigational product AXPAXLI, with promising clinical trial results, while also preparing for a key NDA submission later this year.

July 09, 2026 Ocular Therapeutix Inc. Grants Inducement Awards to New Employees Ocular Therapeutix Inc. has granted inducement awards to eleven new employees, including stock options and restricted stock units, to attract talent. This initiative supports the company's growth as it advances its clinical pipeline for retinal diseases. Key products in development include AXPAXLI™ and DEXTENZA®.

July 01, 2026 Ocular Therapeutix Inc. Sets Stage for July Scientific and Investor Conferences Ocular Therapeutix, Inc. will participate in major scientific and investor conferences in July 2026 to showcase its advancements in retinal therapies. Key presentations include findings from the Phase 3 SOL-1 Trial and discussions on FDA guidance's impact on drug development.

June 22, 2026 Ocular Therapeutix Inc. Announces Inducement Grants to Enhance Leadership Team Ocular Therapeutix has announced inducement grants to Kelley Allison, aimed at strengthening its leadership team as it navigates the biopharmaceutical landscape. This strategic move supports the company's focus on market access for its innovative ocular therapies, including its investigational candidate AXPAXLI™. The grants are part of the company's efforts to enhance executive capabilities and drive growth.

June 17, 2026 Ocular Therapeutix Inc. Advances AXPAXLI NDA Submission Plans Ocular Therapeutix is set to submit a New Drug Application for AXPAXLI™ by the end of 2026, following positive results from the SOL-1 trial for wet AMD. The company is also streamlining its diabetic retinopathy program, aiming for a single Phase 3 trial. Experts highlight the potential of AXPAXLI to transform patient care in retinal diseases.

June 05, 2026 Ocular Therapeutix Inc. Expands Workforce with Inducement Grants Ocular Therapeutix has issued inducement equity awards to seven new employees as part of its growth strategy in the biopharmaceutical sector. With stock options and restricted stock units, the company aims to attract top talent and align employee interests with corporate performance, supporting its innovative pipeline in ocular treatments.

June 04, 2026 Ocular Therapeutix Inc. to Showcase Groundbreaking Innovations at Clinical Trials at the Summit 2026 Ocular Therapeutix will showcase its innovative retinal therapies at the Clinical Trials at the Summit 2026, featuring key presentations on OTX-TKI and its Phase 3 trial outcomes. The event promises insights into the future of retinal disease treatment and the impact of innovation on patient care.

June 02, 2026 Ocular Therapeutix Inc. Announces Investor Day Set for June 17, 2026 Ocular Therapeutix will host an Investor Day on June 17, 2026, in NYC, highlighting updates on their investigational product AXPAXLI and featuring discussions with key opinion leaders in retinal treatments. The event aims to engage investors in the company’s strategic approach to advancing therapies for retinal diseases.

May 15, 2026 Ocular Therapeutix Inc. Announces Inducement Grants for New HR Leader Ocular Therapeutix has granted inducement equity awards to Amy Ricca, its new Senior VP of HR, to attract top talent. The awards include stock options and restricted stock units, aimed at fostering leadership in the company's innovative retinal treatments.

May 05, 2026 Ocular Therapeutix Reports Strong Q1 2026 Financial Results and Key Developments Ocular Therapeutix reported strong Q1 2026 financial results, highlighting the success of AXPAXLI in wet AMD trials. The company is positioned for significant growth with ongoing clinical studies and a robust pipeline.

May 05, 2026 Ocular Therapeutix Inc. Reports Promising Q1 2026 Results Amidst Clinical Advancements Ocular Therapeutix Inc. announced promising Q1 2026 results, highlighting significant advancements in their AXPAXLI trials for wet AMD. Despite a net loss of $88.6 million, the company maintains a strong financial position with $666.7 million in cash, paving the way for future growth and potential regulatory submissions.

April 29, 2026 Ocular Therapeutix Commences SOL-X Trial for AXPAXLI in Wet AMD Ocular Therapeutix has enrolled its first patient in the SOL-X trial, a pivotal study evaluating the long-term safety and efficacy of AXPAXLI for wet AMD. This trial aims to improve treatment outcomes and patient retention, following the promising results of earlier trials.

April 28, 2026 Ocular Therapeutix Inc. Set to Announce First Quarter 2026 Financial Results Ocular Therapeutix, Inc. will report its Q1 2026 financial results on May 5, 2026, with a conference call for investors. The company focuses on innovative retinal treatments and is currently advancing clinical trials for its product AXPAXLI™.

April 27, 2026 Ocular Therapeutix Inc. Gears Up for May Conferences: A Focus on Innovation in Retinal Care Ocular Therapeutix, Inc. is set to present at several key conferences in May 2026, highlighting advancements in retinal care, including their investigational product AXPAXLI™. The events will feature presentations from leading experts, focusing on innovative approaches to retinal diseases.

April 22, 2026 Ocular Therapeutix to Host Investor Day: A Focus on Retinal Innovation Ocular Therapeutix will host an Investor Day on June 17, 2026, in NYC, focusing on advancements in retinal disease treatments. The event aims to engage investors with insights into their innovative product pipeline, including the investigational AXPAXLI™. A live webcast will ensure broader participation.

April 14, 2026 Ocular Therapeutix Inc. Announces Inducement Grants Under Nasdaq Listing Rule Ocular Therapeutix, Inc. has granted inducement awards to six new employees and its new SVP, Jerome Gangitano, as part of its talent attraction strategy. The equity awards include stock options and restricted stock units, aimed at fostering innovation in the biopharmaceutical field.

April 13, 2026 Ocular Therapeutix Inc. Reports Breakthrough Week 52 Data in Wet AMD Treatment Trial Ocular Therapeutix presents compelling data from the SOL-1 Phase 3 trial of AXPAXLI, highlighting its efficacy and safety in treating wet AMD. Key findings show significant visual acuity gains and sustained disease control. The company plans to submit a New Drug Application based on these results.

April 01, 2026 Ocular Therapeutix Inc. Unveils New Data on SOL-1 Ahead of April Conferences Ocular Therapeutix Inc. is set to present crucial data on its investigational product candidate SOL-1 at upcoming April conferences. The extended-release hydrogel formulation of dexamethasone aims to enhance treatment for ocular conditions, potentially revolutionizing patient care through improved efficacy and safety.

March 09, 2026 Ocular Therapeutix Inc. Announces Inducement Grants to New Employees Ocular Therapeutix Inc. has granted inducement awards to three new hires, aiming to bolster its talent pool for innovative retinal therapies. The awards include stock options and RSUs, reflecting the company’s dedication to attracting top talent as it progresses in its clinical trials and product development.

February 24, 2026 Ocular Therapeutix Inc. Set to Showcase Innovations at March Investor Conferences Ocular Therapeutix will participate in major investor conferences in March 2026, showcasing its innovative pipeline in retinal therapies. CEO Dr. Pravin U. Dugel will lead discussions, emphasizing the company's commitment to advancing ocular health.

February 23, 2026 Ocular Therapeutix Inc. to Present Groundbreaking SOL-1 Data at 49th Macula Society Annual Meeting Ocular Therapeutix will present SOL-1 trial results for AXPAXLI at the 49th Macula Society Annual Meeting on February 27, 2026. The symposium will offer key insights into retinal therapies and follow with a live investor webcast on March 2, 2026.

February 17, 2026 Ocular Therapeutix Inc. Reports Groundbreaking Results from SOL-1 Phase 3 Trial for Wet AMD Ocular Therapeutix has announced promising results from its SOL-1 Phase 3 trial for AXPAXLI, showing superior efficacy over aflibercept in wet AMD treatment. With significant improvements in visual acuity and durability, AXPAXLI could revolutionize patient care in retinal therapy.

February 13, 2026 Ocular Therapeutix Set to Unveil Topline Data for AXPAXLI™ in Wet AMD Ocular Therapeutix will present topline data from its SOL-1 Phase 3 trial for AXPAXLI™, a treatment for wet AMD, on February 17, 2026. This data could significantly impact the management of this common cause of vision loss. A subsequent presentation will occur at the 49th Macula Society Annual Meeting.

February 06, 2026 Ocular Therapeutix Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocular Therapeutix has granted inducement awards to five new employees to attract talent and enhance its commitment to retinal therapy innovation. The awards include stock options and RSUs, with a strategic vesting schedule aimed at long-term employee engagement.

February 05, 2026 Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results Ocular Therapeutix reported its Q4 and full-year 2025 financial results, revealing a decline in revenue but strong cash reserves. Upcoming trial results for AXPAXLI could influence the company's future in retinal disease treatment significantly.

February 05, 2026 Ocular Therapeutix Inc. Reports 2025 Annual Results: Navigating Challenges and Seizing Opportunities Ocular Therapeutix Inc. reported its 2025 annual results, showcasing key advancements in its product pipeline, particularly AXPAXLI for retinal diseases. Despite facing financial challenges, including significant net losses, the company remains focused on innovative treatments and maintaining a strong cash position for future growth.

January 23, 2026 Ocular Therapeutix Inc. Grants Inducement Awards to New CCO Ocular Therapeutix has appointed David W. Robinson as its new Global Chief Commercial Officer, granting him significant stock options and RSUs. This strategic move is aimed at enhancing the company's leadership and advancing its innovative pipeline in retinal health.

January 21, 2026 Ocular Therapeutix Inc. Strengthens Leadership with New Global Chief Commercial Officer Ocular Therapeutix has appointed David W. Robinson as Global Chief Commercial Officer to strengthen its leadership as it prepares for the launch of AXPAXLI, an innovative therapy for retinal diseases. Robinson's extensive experience in ophthalmology and strategic launch planning is expected to drive the company's commercial success and reshape treatment methodologies.

December 08, 2025 Ocular Therapeutix Accelerates NDA Submission Timeline for AXPAXLI™ in Wet AMD Ocular Therapeutix is expediting its NDA submission for AXPAXLI, an innovative treatment for wet AMD, based on promising Phase 3 trial data. The company aims to address critical unmet needs in ocular health by potentially transforming treatment protocols and improving patient adherence.

December 05, 2025 Ocular Therapeutix Inc. Announces Inducement Grants to New Employees Ocular Therapeutix has awarded inducement equity grants to eight new employees, including stock options and RSUs, to attract top talent. This strategic move aims to align employee interests with company goals while continuing to innovate in retinal disease treatments.

November 24, 2025 Ocular Therapeutix Inc. Begins HELIOS-3 Phase 3 Trial for AXPAXLI in Diabetic Retinopathy Ocular Therapeutix has initiated the HELIOS-3 Phase 3 trial for AXPAXLI, targeting non-proliferative diabetic retinopathy. This innovative treatment aims to improve patient outcomes by reducing the frequency of interventions. The trial introduces a novel endpoint for assessing treatment effectiveness.

November 12, 2025 Ocular Therapeutix Inc. Announces Upcoming Investor Conferences Ocular Therapeutix is set to participate in notable investor conferences in November and December 2025, featuring discussions on its innovative pipeline led by CEO Pravin U. Dugel. With a focus on retinal treatments, the company aims to enhance visibility and stakeholder engagement.

November 07, 2025 Ocular Therapeutix Inc. Announces Inducement Grant to New Employee Ocular Therapeutix has granted an inducement award to a new employee, featuring stock options and restricted stock units to attract top talent. This strategic move aims to enhance the company's innovative pipeline in ocular therapies, including ongoing clinical trials and new product developments.

November 04, 2025 Ocular Therapeutix Achieves Milestone in Clinical Trial for Wet AMD Treatment Ocular Therapeutix has reached the target randomization in its SOL-R trial for AXPAXLI, aimed at treating wet AMD. This milestone is crucial for developing durable therapies, with topline results anticipated in 2027.

November 04, 2025 Ocular Therapeutix Inc. Reports Third Quarter 2025 Financial Results and Business Highlights Ocular Therapeutix reported significant Q3 2025 financial results, revealing a net loss of $69.4 million. The company highlighted milestones in clinical trials for AXPAXLI™ aimed at advancing treatments for wet AMD and diabetic retinopathy.

November 04, 2025 Ocular Therapeutix Inc. Reports Q3 2025 Financial Results: A Mixed Bag Amid Clinical Advancements Ocular Therapeutix Inc. reported a net loss of $69.41 million in Q3 2025, despite promising clinical advancements for AXPAXLI. The company faces financial challenges but remains optimistic about its ocular treatments pipeline.

October 28, 2025 Ocular Therapeutix Inc. Set to Announce Third Quarter Financial Results Ocular Therapeutix is set to announce its third quarter financial results on November 4, 2025. The company will discuss its advancements in retinal disease treatments, including the promising AXPAXLI™ and DEXTENZA® therapies. Investors can join the conference call for crucial insights into its performance and future strategies.

October 07, 2025 Ocular Therapeutix Inc. Announces Participation in Key Scientific Conferences Ocular Therapeutix Inc. announces its participation in key scientific conferences where it will present innovative research in ophthalmology, including findings from its latest clinical trials. The company highlights its commitment to redefining retinal treatments with products like AXPAXLI™ and DEXTENZA®.

September 30, 2025 Ocular Therapeutix Inc. Showcases Promising Developments at Investor Day Ocular Therapeutix showcased its promising developments at the Investor Day, focusing on AXPAXLI's trials for wet AMD and diabetic retinopathy. Key insights included the potential for a superiority label, enhancing patient care through reduced treatment frequency, and innovative trial designs aiming for regulatory approval.

September 30, 2025 Ocular Therapeutix Inc. Announces Major Stock Offering Ocular Therapeutix, Inc. announced a major stock offering of 37.9 million shares at $12.53 each, raising approximately $475 million. The funds will support clinical trials for AXPAXLI and enhance manufacturing capabilities, positioning the company for future growth in retinal treatments.

August 05, 2025 Ocular Therapeutix Inc. Reports Q2 2025: Navigating Challenges and Clinical Advancements Ocular Therapeutix Inc. reports its Q2 2025 results, highlighting progress in AXPAXLI trials for wet AMD but facing revenue challenges, with a notable decline in net product revenue. The FDA's recent approval for pediatric use of DEXTENZA may help offset these challenges as the company navigates its financial landscape.

May 05, 2025 Ocular Therapeutix Inc. Reports 2025 Q1 Results: Navigating Challenges and Advancing Innovations Ocular Therapeutix's Q1 2025 results show a 27.7% revenue decline to $10.6 million, despite ongoing clinical advancements with AXPAXLI for retinal diseases. The company remains optimistic about future sales growth and continued investments in innovative treatments.

March 31, 2025 Ocular Therapeutix Inc. Gears Up for Investor Engagement in April 2025 Ocular Therapeutix is set to engage investors at two key conferences in April 2025, presenting its innovative product pipeline and strategic vision. With a focus on retinal therapies, Ocular aims to strengthen investor relationships and showcase advancements in ocular therapeutics.

March 07, 2025 Ocular Therapeutix Inc. Announces Inducement Grants to New Hire Ocular Therapeutix has issued inducement grants to a new hire, including stock options and restricted stock units, to bolster its innovative retinal therapies. This move highlights the company’s dedication to attracting top talent as it advances its clinical pipeline, particularly with its lead product AXPAXLI.

March 03, 2025 Ocular Therapeutix Inc. Reports Strong Progress in Fourth Quarter and Full Year 2024 Ocular Therapeutix showcased strong financial results and clinical advancements in 2024, particularly with AXPAXLI aimed at treating wet AMD. The company anticipates further developments in 2025 while maintaining robust cash reserves to support ongoing trials.

March 03, 2025 Ocular Therapeutix Inc. Reports 2024 Annual Results: A Year of Growth Amidst Challenges Ocular Therapeutix Inc. reported a revenue increase to $63.5 million in 2024, driven by DEXTENZA sales. However, the company faced a net loss of $193.5 million due to rising expenses in R&D. The outlook remains optimistic as they advance their clinical pipeline in a growing market.

February 25, 2025 SWOT Analysis of Ocular Therapeutix Inc. in 2025 This SWOT analysis examines Ocular Therapeutix Inc.'s strengths, such as its innovative product pipeline and proprietary technology, alongside its financial weaknesses and market threats. It also discusses growth opportunities in emerging markets and the challenges posed by competition and regulatory hurdles.

February 25, 2025 Ocular Therapeutix Inc. Gears Up for Investor Engagement in March 2025 Ocular Therapeutix, a leader in retinal therapies, will participate in two investor conferences in March 2025. Key presentations by CEO Dr. Pravin U. Dugel will highlight the company's advancements, including its flagship product AXPAXLI for treating wet AMD.

February 24, 2025 Ocular Therapeutix Inc. to Reveal 2024 Financial Results and Business Updates Ocular Therapeutix will host a conference call on March 3, 2025, to discuss its Q4 and full-year 2024 financial results and business updates. The company is advancing innovative treatments for retinal diseases, including AXPAXLI and DEXTENZA.

November 14, 2024 Ocular Therapeutix Inc. Releases Q3 2024 Financial Report: A Look at Growth and Challenges Ocular Therapeutix's Q3 2024 report reveals progress in clinical trials for innovative ocular therapies, though financial losses have increased significantly. The company remains focused on advancing its promising products despite ongoing challenges.

August 07, 2024 Ocular Therapeutix Inc. Reports Q2 2024 Financial Results: A Mixed Bag of Growth and Challenges Ocular Therapeutix Inc. reported a 9% increase in Q2 2024 revenue, totaling $16.4 million, but faced a substantial net loss of $43.77 million. The company continues to advance its product pipeline while navigating operational challenges and improving its balance sheet.

May 07, 2024 Ocular Therapeutix Inc. Reports Q1 2024 Financial Results: A Look at Growth and Challenges Ocular Therapeutix Inc. reports Q1 2024 financial results, highlighting an 11.8% revenue growth driven by DEXTENZA, despite rising operational costs leading to a net loss of $64.8 million. The company faces challenges in managing expenses while advancing its innovative ocular therapies.

Ocular Therapeutix Inc. Unveils New Data on SOL-1 Ahead of April Conferences

Last updated: April 01, 2026 •

Taurigo

1. Promising Developments in Drug Delivery Technology

Ocular Therapeutix Inc., a leading biopharmaceutical company focused on the development of innovative therapies for eye diseases and conditions, has announced that it will present additional data and analyses regarding its product candidate, SOL-1, at several scientific conferences scheduled for April 2026. This announcement comes as the company continues to make strides in the field of ocular drug delivery.

2. SOL-1: A Game Changer in Ocular Treatment

SOL-1 is an investigational extended-release hydrogel formulation of dexamethasone designed to treat various ocular conditions. The data shared at the upcoming conferences is expected to provide further insights into the product's efficacy, safety, and overall performance in comparison to existing therapies. This technology has the potential to revolutionize the treatment landscape for patients suffering from eye-related ailments, offering longer-lasting effects with fewer administrations.

3. Key Insights to be Presented

The presentations will focus on various aspects of SOL-1, including:

Efficacy and Safety Profiles: Detailed results from recent clinical trials that evaluate the therapeutic benefits of SOL-1.

Patient Outcomes: An analysis of how SOL-1 impacts patient quality of life and treatment adherence.

Comparative Studies: Insights comparing SOL-1's performance against standard treatment options, demonstrating its potential advantages.

These findings are highly anticipated among the scientific community and stakeholders, as they could play a pivotal role in the future approval and commercialization of SOL-1.

4. Conferences on the Horizon

Ocular Therapeutix will be presenting at multiple prestigious conferences throughout April, though specific details regarding the venues and dates have yet to be disclosed. These conferences are known for showcasing cutting-edge research and innovations in the field of ophthalmology, providing an excellent platform for the company to highlight its advancements in ocular therapies.

5. Market Implications

The additional data on SOL-1 could have significant implications for Ocular Therapeutix's market position. If the findings are favorable, they may bolster investor confidence and increase the likelihood of partnerships or collaborations with larger pharmaceutical companies. Furthermore, successful trial results could expedite the regulatory approval process, paving the way for SOL-1 to reach the market sooner.

6. Conclusion

As Ocular Therapeutix prepares to share its latest findings on SOL-1, eyes will be on the company to see if it can deliver groundbreaking results that could transform the treatment of ocular conditions. With April conferences on the horizon, the industry eagerly awaits the unveiling of this crucial data, which could define the future trajectory of both Ocular Therapeutix and the broader field of ocular therapeutics.

Original press release

You may also be interested in: